首页> 外国专利> Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

机译:破坏肌动蛋白细胞骨架组织的药物上调III型内皮细胞一氧化氮合酶

摘要

A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include hypoxia-induced conditions. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
机译:提供了用于破坏肌动蛋白细胞骨架组织的药剂的用途。在本发明中,发现破坏肌动蛋白细胞骨架组织的试剂上调了内皮细胞一氧化氮合酶活性。结果,破坏肌动蛋白细胞骨架组织的试剂可用于治疗或预防由内皮细胞一氧化氮合酶的异常低表达和/或活性引起的疾病。这样的状况包括缺氧引起的状况。被认为主要从此类治疗中受益的受试者包括非高脂血症和非高胆固醇血症,但不一定排除高脂血症和高胆固醇血症。

著录项

  • 公开/公告号US2003013703A1

    专利类型

  • 公开/公告日2003-01-16

    原文格式PDF

  • 申请/专利权人 LIAO JAMES K.;

    申请/专利号US20020144669

  • 发明设计人 JAMES K. LIAO;

    申请日2002-05-13

  • 分类号A61K31/551;A61K31/496;A61K31/15;

  • 国家 US

  • 入库时间 2022-08-22 00:09:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号